Tenet Healthcare (THC)
(Real Time Quote from BATS)
$132.14 USD
-3.70 (-2.72%)
Updated Jul 5, 2024 01:22 PM ET
3-Hold of 5 3
A Value B Growth A Momentum A VGM
Price, Consensus and EPS Surprise
THC 132.14 -3.70(-2.72%)
Will THC be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for THC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for THC
Zacks.com featured highlights include Tenet Healthcare, Leidos Holdings, Atmos Energy and Cabot
Here's Why You Should Retain Ensign Group (ENSG) Stock Now
THC: What are Zacks experts saying now?
Zacks Private Portfolio Services
4 Stocks That Boast Remarkable Interest Coverage Ratio
Zacks.com featured highlights include Amkor Technology, Tenet Healthcare, Leidos and Maximus
Community Health (CYH) & Cost Plus Drugs Expand Collaboration
Other News for THC
Deutsche Numis Reaffirms Their Buy Rating on Tenet Healthcare (THC)
Tenet Healthcare price target raised by $5 at Deutsche Bank, here's why
Tenet Healthcare Reaches Analyst Target Price
February 2025 Options Now Available For Tenet Healthcare (THC)
Long-term beneficiaries of AI, according to Goldman Sachs